Search results for "Cathepsin K"

showing 7 items of 17 documents

Toward very potent, non-covalent organophosphonate inhibitors of cathepsin C and related enzymes by 2-amino-1-hydroxy-alkanephosphonates dipeptides

2013

Cathepsins play an important role in several human disorders and therefore the design and synthesis of their inhibitors attracts considerable interest in current medicinal chemistry approaches. Due to the presence of a strong sulphydryl nucleophile in the active center of the cysteine type cathepsins, most strategies to date have yielded covalent inhibitors. Here we present a series of non-covalent β-amino-α-hydroxyalkanephosphonate dipeptidic inhibitors of cathepsin C, ranking amongst the best low-molecular weight inhibitors of this enzyme. Their binding modes determined by molecular modelling indicate that the hydroxymethyl fragment of the molecule, not the phosphonate moiety, acts as a t…

Models MolecularStereochemistryhydroxyphosphonateBiochemistryCathepsin CCathepsin BCathepsin CInhibitory Concentration 50chemistry.chemical_compoundCathepsin OTransition state analogCathepsin KHumanscysteine proteasePeptide bondcathepsinAminesEnzyme InhibitorsCathepsinDipeptideChemistryMolecular MimicryDipeptidesGeneral MedicineOrganophosphatesEnzyme ActivationinhibitorBiochemistryHydroxy AcidsBiochimie
researchProduct

New molecular targets in bone metastases.

2010

Bone metastases have a major impact on morbidity and on mortality in cancer patients. Despite its clinical relevance, metastasis remains the most poorly elucidated aspect of carcinogenesis. The biological mechanisms leading to bone metastasis establishment have been referred as " vicious circle," a complex network between cancer cells and the bone microenvironment. This review is aimed to underline the new molecular targets in bone metastases management other than bisphosphonates. Different pathways or molecules such as RANK/RANKL/OPG, cathepsin K, endothelin-1, Wnt/DKK1, Src have recently emerged as potential targets and nowadays preclinical and clinical trials are underway. The results fr…

Oncologymedicine.hormonemedicine.medical_specialtyPathologyCathepsin KProto-Oncogene Proteins pp60(c-src)Antineoplastic AgentsBone NeoplasmsBone NeoplasmAntibodies Monoclonal HumanizedEndothelinMetastasisAntineoplastic AgentEndothelinsBone metastases; Molecular targets; Animals; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antineoplastic Agents; Bone Neoplasms; Cathepsin K; Denosumab; Endothelins; Humans; Proto-Oncogene Proteins pp60(c-src); RANK Ligand; Medicine (all); Oncology; Radiology Nuclear Medicine and ImagingInternal medicineMedicineAnimalsHumansRadiology Nuclear Medicine and imagingMolecular targetbiologyAnimalbusiness.industryMedicine (all)EndothelinsRANK LigandCancerBone metastasisAntibodies MonoclonalGeneral Medicinemedicine.diseaseClinical trialBone metastaseDenosumabOncologyRANKLCancer cellbiology.proteinDenosumabbusinessHumanmedicine.drugCancer treatment reviews
researchProduct

Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation

2015

Bone disease is the most frequent complication in multiple myeloma (MM) resulting in osteolytic lesions, bone pain, hypercalcemia and renal failure. In MM bone disease the perfect balance between bone-resorbing osteoclasts (OCs) and bone-forming osteoblasts (OBs) activity is lost in favour of OCs, thus resulting in skeletal disorders. Since exosomes have been described for their functional role in cancer progression, we here investigate whether MM cell-derived exosomes may be involved in OCs differentiation. We show that MM cells produce exosomes which are actively internalized by Raw264.7 cell line, a cellular model of osteoclast formation. MM cell-derived exosomes positively modulate pre-…

Pathologymedicine.medical_specialtyCellular differentiationCellOsteoclastsMMP9BiologyExosomesMiceOsteoclastMultiple myelomaSettore BIO/13 - Biologia ApplicatamedicineCathepsin KAnimalsHumansExosomes Multiple MyelomaMultiple myelomaTumor microenvironmentMicroscopy ConfocalBone FormationCell Differentiationmedicine.diseaseMicrovesiclesRAW 264.7 Cellsmedicine.anatomical_structureOncologyTumor microenvironmentCancer researchOsteoclastExosomes Multiple Myeloma; Osteoclasts; Bone FormationResearch PaperSignal Transduction
researchProduct

Inflammation in the Human Periodontium Induces Downregulation of the α1- and β1-Subunits of the sGC in Cementoclasts

2021

Nitric oxide (NO) binds to soluble guanylyl cyclase (sGC), activates it in a reduced oxidized heme iron state, and generates cyclic Guanosine Monophosphate (cGMP), which results in vasodilatation and inhibition of osteoclast activity. In inflammation, sGC is oxidized and becomes insensitive to NO. NO- and heme-independent activation of sGC requires protein expression of the &alpha

Periodontium0301 basic medicinealveolar bonecementoclastslcsh:Chemistrychemistry.chemical_compound0302 clinical medicineCathepsin Kheterocyclic compoundsperiodontitisCyclic GMPlcsh:QH301-705.5SpectroscopyGeneral MedicineComputer Science ApplicationsResorptionCell biologymedicine.anatomical_structurecardiovascular systemOxidation-Reductioncementuminorganic chemicalsPeriodontal LigamentIronAntigens Differentiation MyelomonocyticHemeArticleCatalysisNitric oxideInorganic Chemistry03 medical and health sciencesstomatognathic systemAntigens CDnitric oxideOsteoclastmedicineAnimalsHumansddc:610CementumPhysical and Theoretical ChemistryMolecular BiologyCyclic guanosine monophosphateInflammationOrganic Chemistrysoluble guanylyl cyclase030206 dentistryPeriodontiumcGMPosteoclasts030104 developmental biologyGene Expression Regulationlcsh:Biology (General)lcsh:QD1-999chemistrySoluble guanylyl cyclaseInternational Journal of Molecular Sciences
researchProduct

Peptide-Capped Mesoporous Nanoparticles: Toward a more Efficient Internalization of Alendronate

2020

[EN] Osteoporosis is an illness which appears when the osteoblast/osteoclast activities are unbalanced taking place bone resorption (caused by osteoclasts) in higher extension than bone formation (induced by osteoblasts). Alendronate is one of the most used drugs for osteoporosis treatment despite its scarce bioavailability. Here we present the synthesis and characterization of mesoporous gated nanoparticles (two sets) for the controlled release of alendronate. The first set of nanoparticles (S1) were loaded with sulforhodamine B and capped with a peptide that could be selectively hydrolyzed by cathepsin K enzyme (overexpressed in osteoclasts). The second set (S2) was functionalized with am…

chemistry.chemical_classificationAlendronateChemistrymedia_common.quotation_subjectCathepsin KQUIMICA INORGANICANanoparticlePeptideGeneral ChemistryCombinatorial chemistryEnzymesQUIMICA ORGANICANanoparticlesOsteoporosisMesoporous materialInternalizationmedia_common
researchProduct

Cathepsin L in Normal and Pathological Bone Remodeling

2011

Abstract Cathepsin L is a ubiquitous lysosomal cysteine endopeptidase that is mainly involved in the metabolic turnover of intracellular proteins. However, it is now well established that this enzyme may also be implicated in the regulation of other important biological processes includ- ing bone resorption. Therefore, altered expression levels of Cathepsin L may result in disturbances of bone homeo- stasis and, eventually, in the onset of pathological condi- tions associated with altered bone turnover. These observations support the concept that Cathepsin L may be regarded as an additional target for the development of novel therapeutic options for the treatment of patients with bone disea…

chemistry.chemical_classificationmedicine.medical_specialtybiologyEndocrinology Diabetes and MetabolismBone metastasisBone diseases Bone metastasis Cancer Cathepsin L Cysteine proteinases Proteinase inhibitorsmedicine.diseaseBone resorptionCell biologyBone remodelingCathepsin LEndocrinologyEndocrinologyEnzymechemistryInternal medicinemedicineCathepsin Kbiology.proteinOrthopedics and Sports MedicinePathologicalHomeostasisClinical Reviews in Bone and Mineral Metabolism
researchProduct

Effects of Zoledronic Acid on Cathepsin K circulating levels in patients with bone metastasis.

2007

Cathepsin K serum levels were determinated in patients with bone metastases from breast cancer or prostate cancer in therapy with zoledronic acid or in patients or in patients with located breast or prostate cancer end in patients with non malignant diseases and in healthy blood. donors (control group). Cathepsin K serum levels were significantly more eleved in healthy subjects or in patients with peimary osteoporosis. Furthermore, the administration of Zoledronic acid to patients with metastatic bome disease from breast or prostate cancer, induced a marked increase of Cathepsin K serum levels.

zoledronic acid cathepsin k bone metastases
researchProduct